Conference Reports for NATAP

Back

AIDS 2022 July 29 - Aug 2 24th Intl AIDS Conference     In Vitro Release and In Vivo PK of Antiretroviral Drugs from Ultra-Long-Acting Polymeric Implants: Towards Better Outcomes for HIV Prevention and Treatment - (02/13/23)   Randomised study of switch to DTG/RPV in subjects with HIV RNA <50c/ml and archived K103N over 48 weeks - (08/15/22)   Randomised study of switch to DTG/RPV in subjects with HIV RNA <50c/ml and archived K103N over 48 weeks - (08/15/22)   Causes of death for persons with HIV in an integrated healthcare system in Northern California, 2013-2017 - (08/15/22)   WHO LA-CAB PrEP Guidelines at IAS 2022 - (08/13/22)   A phase IV open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to HIV-1 - (08/11/22)   Supporting Achievement of the State of Georgia's 25% HIV Incidence Reduction Target Among MSM: A Mathematical Model to Evaluate the Potential Impact of Long-acting Pre-exposure Prophylaxis in Atlanta - (08/11/22)   Assessment of cardiovascular health using the "Life's Simple 7" among the Canadian HIV and Aging Cohort study participants: a cross-sectional observational study - (08/11/22)   Risk factors linked to age-related comorbidities among people living with HIV aged over 40 years - (08/11/22)   Advanced HIV infection in the US: immune response to ART initiation - (08/11/22)   Audience Segmentation of Preferences for Long-Acting Injectable PrEP Among U.S. MSM: A Latent Class Analysis - (08/11/22)   Willingness & Preferences for Long-Acting Injectable PrEP Among US Men Who Have Sex with Men: A discrete choice experiment - (08/11/22)   High prevalence of asymptomatic Omicron carriage and correlation with CD4 T cell count among adults with HIV enrolling in COVPN 3008 Ubuntu clinical trial in sub-Saharan Africa - (08/10/22)   HIV/HBV coinfection in pregnancy and response to antiretroviral therapy - (08/09/22)   Incidence and disease severity of non-alcoholic fatty liver disease among people living with HIV in Thailand - (08/09/22)   HIV in 2022 and beyond: A view from NIAID - non-adherence, disengagement from care, PrEP, vaccine - cure research - (08/09/22)   Bacterial translocation of LPS is associated with lower cognitive abilities in men living with HIV receiving antiretroviral therapy - (08/09/22)   Use of the Patient Generated Index to identify physical health challenges among people living with HIV - (08/09/22)   Early Implementation and Clinical Outcomes of Long-Acting Injectable Cabotegravir and Rilpivirine in a Safety-Net Clinic - (08/09/22)   Assessment of cardiovascular health using the "Life's Simple 7" among the Canadian HIV and Aging Cohort study participants: a cross-sectional observational study - (08/09/22)   Burden of chronic comorbidities among people living with and without HIV: disability-adjusted life years in British Columbia, Canada - (08/09/22)   Selection of Cabotegravir Dosing Regimens For HIV Treatment and Pre-Exposure Prophylaxis (PrEP) in Adolescents by Leveraging Adult Data - (08/09/22)   Association of prenatal PrEP exposure with neurodevelopmental and growth outcomes beyond 24 months among Kenyan children - (08/09/22)   Determinants of long-term survival in late HIV diagnosed individuals: the PISCIS Cohort study - (08/09/22)   High HIV incidence and mortality in a multi-site cohort of transgender women in the eastern and southern United States - (08/09/22)   Prevalence of adverse birth outcomes and external birth defects among women living with HIV in Malawi - (08/09/22)   Chronic injection opioid use increases the systemic inflammation and T cell immune activation in virally suppressed people living with HIV - each separately HIV & Opioid Use increase immune activation, inflammation - (08/09/22)   Arterial remodeling is associated with CD4 T cell count and plasma IL-10 in persons with HIV - (08/08/22)   Age Associated with Comorbidites in Spain - Risk factors linked to age-related comorbidities among people living with HIV aged over 40 years - (08/08/22)   Comorbidity Rate Rose 1% to 2% Yearly in 2008-2018 for HIV+ in Hospital - Mark Mascolini (08/08/22)   Incidence of cardiometabolic outcomes among people living with HIV initiated on INSTI versus non-INSTI antiretroviral therapies Integrase Inhibitor in First ART Poses Some Cardio Risks in Big US Analysis - Mark Mascolini(08/07/22)   Characterization of the absorption, metabolism, and excretion of islatravir, an HIV nucleoside reverse transcriptase translocation inhibitor, in humans - (08/07/22)   No pharmacokinetic interaction between islatravir and methadone - (08/07/22)   Resistance mutations in the HIV integrase coding region among INSTI-naïve pregnant women in Argentina: a baseline survey - (08/07/22)   Weight Gain After Antiretroviral Therapy Initiation in People Living with HIV - (08/07/22)   Weight Gain After Non-nucleoside Reverse Transcriptase-to-Integrase Inhibitor Switch in the United States - (08/07/22)   Current Pain, Black Race, Age Tied to Higher Frailty Risk With HIV in USA - Mark Mascolini (08/07/22)   INSTIs Plus PIs-But Not INSTIs Alone-Tied to Rising Body Mass Index in Children - Mark Mascolini (08/07/22)   Alcohol, Smoking, Drugs, Liver Disease-But Not TDF-Predict Fracture With HIV - Mark Mascolini (08/07/22)   Long-term Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide (F/TAF) With a Third Agent in Children Living With HIV - (08/07/22)   Long-term Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide (F/TAF) With a Third Agent in Children Living With HIV - (08/06/22)   Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Long-Acting Lenacapavir for Treatment of HIV - (08/06/22)   One Year Outcome of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Children ≥ 2 Years Weighing 14 to < 25 kg - (08/06/22)   Long-Acting Cabotegravir + Rilpivirine Injection Site Reactions: Pooled Week 96 Results - (08/06/22)   Factors Associated with Healthcare Providers' Preference for Forgoing an Oral Lead-in Phase when Initiating Long-acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial - (08/06/22)   Initiating long-acting cabotegravir and rilpivirine in a real-world setting: clinical characteristics and switch reasons from PLHIV and health care provider perspective in the German CARLOS cohort - (08/06/22)   Safety and Effectiveness From the CARISEL Study: Phase 3b Hybrid-III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings - (08/06/22)   What women want - results [survey] from discrete choice experiment about preferred PrEP method from Khomas region of Namibia - (08/06/22)   "Give It a Shot": Best Practices From HCPs for Administering Long-Acting Cabotegravir + Rilpivirine - (08/05/22)   Low Level of Virologic Failure and Resistance in ART-Experienced, Integrase Inhibitor-Naive Participants Receiving Dolutegravir (DTG) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Combined Regimens: 10-Year Follow-up in the SAILING Study - (08/05/22)   Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study in Spain - (08/05/22)   Efficacy and Safety of Switching to Dolutegravir/Lamivudine by Baseline Regimen in Virologically Suppressed Adults: 48-Week Pooled Analysis - (08/05/22)   Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Experienced, Virologically Suppressed PLHIV Aged ≥50 Years: Pooled Results From the TANGO and SALSA Studies - (08/05/22)   REAL-WORLD TREATMENT EXPERIENCE OF SINGLE TABLET DOLUTEGRAVIR/LAMIVUDINE IN THE US: RESULTS FROM THE TANDEM STUDY - (08/05/22)   Switching to dolutegravir/lamivudine two-drug regimen: durability and virologic outcomes in routine U.S. clinical care - (08/05/22)   Improvements in Patient-Reported Outcomes in Older Adults Aged ≥50 Years With HIV-1 After Switching to a 2-Drug Regimen of Fixed-Dose Combination DTG/3TC: 48-Week Results From the SALSA Study - (08/05/22)   A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG) use during pregnancy: Data from DOLOMITE-NEAT ID Network study - (08/05/22)   Pharmacokinetics of a simplified subcutaneous lenacapavir regimen versus Phase 2/3 regimen - (08/05/22)   Simulations for once weekly dosing of oral lenacapavir - (08/05/22)   Exceptional Post-Treatment HIV Control in an Acute HIV-Infected Woman During More than 15 Yearsbr Exceptional post-treatment control associated with strong NK and gamma delta ? cytotoxic T cells - (08/05/22)   ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced - (08/03/22)   An immunological signature for subclinical atherosclerosis in people living with HIV-1 receiving antiretroviral therapy - (08/03/22)   Putting HBV/HCV Testing and Treatment in HIV Clinics Has Benefits in Vietnam - Mark Mascolini - (08/03/22)   Changes in Inflammatory Biomarkers and Baseline Variables After Switching to Dolutegravir/Lamivudine (DTG/3TC) in 2 Randomized Clinical Trials of Virologically Suppressed Adults: 48-Week Pooled Analysis - (08/03/22)   Disappointing Results With VRC01 bNAb Plus ART to Limit Infant Reservoirs - Mark Mascolini - (08/03/22)   Arrests, City Stress, Life Events Tied to Suicide Attempts in Young With HIV - Mark Mascolini (08/03/22)   High Loneliness Score in Half of Ontario HIV Cohort-Tied to Poor ART Adherence - Mark Mascolini - (08/03/22)   View on Targeted Violence, Being a Teen, Tied to PTSD in US MSM - Mark Mascolini - (08/03/22)   Different Factors Drive Mental Health Desires and Referrals for Black MSM - Mark Mascolini - (08/03/22)   Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study - (08/03/22)   Exceptional Post-Treatment HIV Control in an Acute HIV-Infected Woman During More than 15 Years Exceptional post-treatment control associated with strong NK and gamma delta ? cytotoxic T cells - (08/03/22)   Resistance Analysis of Long-Acting Lenacapavir in Highly Treatment-Experienced People With HIV After 52 Weeks of Treatment - (08/03/22)   Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People With HIV at 54 Weeks - (08/03/22)   Transgender Women (TGW) in HPTN 083: An Evaluation of Safety, Efficacy, and Gender Affirming Hormonal Therapy (GAHT) Interactions with Long-acting Cabotegravir (CAB-LA) - (08/03/22)   The fast and the continuous: dolutegravir-based antiretroviral therapy achieves impressive viral load suppression in CALHIV in the short- and long-term - Mark Mascolini - (08/02/22)   Subcortical brain volumes of children who are HIV-exposed and uninfected in the first three years of life: a South African birth cohort study - (08/02/22)   MSM Used HIV Sex-Negotiating Skills to Protect Themselves From COVID - Mark Mascolini - (08/02/22)   Combining Illicit Drugs Tied to Risky Sex in Mexican MSM - Mark Mascolini - (08/02/22)   Simplified PrEP Dispensing Halves Clinic Visits, Maintains or Improves Adherence in Kenya - Mark Mascolini - (08/02/22)   Depression, Not Gender Identity, Tied to CVD Risk in US HIV+/HIV- Women - Mark Mascolini - (08/02/22)   Trial Finds Neither NTX nor SOF/DCV Can Prevent SARS-CoV-2 - Mark Mascolini - (08/02/22)   Macrophage Activation for 2 Years After Switch From 3 to 2 Antiretrovirals - Mark Mascolini - (08/02/22)   Integrated Screening/Diagnosis for Alcohol, Tobacco, Depression May Extend Life With HIV - Mark Mascolini - (08/02/22)   Smaller Volumes of 2 Brain Regions in Children Exposed to HIV in Utero - Mark Mascolini - (08/01/22)   Survival in advanced AIDS patients treated with efavirenz or dolutegravir in Brazil: a multicenter, observational study - (08/01/22)   Efficacy and safety of dolutegravir plus emtricitabine vs combined antiretroviral therapy for the maintenance of viral suppression: 144-week results of the SIMPL'HIV trial - (08/01/22)   Trends in PrEP Inequity by Race and Census Region, United States, 2012-2021 - (08/01/22)   Dual therapy based on DRVr plus 3TC in HIV-1 naïve patients: global 48 week results from ANDES Study - (08/01/22)   Combined Drinking, Smoking, Depression Tied to Higher Mortality in HIV+ US Women - Mark Mascolini (08/01/22)   Meta-Analysis Confirms Higher COVID Death Risk With HIV - Mark Mascolini (08/01/22)   Low CD4 Count Linked to DAA Failure in People With HIV - Mark Mascolini - (08/01/22)   Frailty Linked to Subclinical Cardio Risk in Older People With/Without HIV - Mark Mascolini - (08/01/22)   Younger Age at Diagnosis of CVD and HTN With HIV Suggests Premature Aging - Mark Mascolini - (08/01/22)   Dolutegravir versus efavirenz-400 as first-line ART in Cameroon: week 192 data of NAMSAL trial - (08/01/22)   Switching From Integrase Inhibitor to PI Trims Weight in HIV Patient Database - Mark Mascolini - (08/01/22)   US Team Offers Fourth Candidate for Stem Cell Transplant HIV Cure - Mark Mascolini - (08/01/22)   Lp(a) in people living with HIV - (08/01/22)   COVID Hospital Death Risk 50% Higher With HIV, WHO Says- Risk Factors Are Under 200 CD4s, CKD, Diabetes, Hypertension - Mark Mascolini - (08/01/22)   Final week 192 results from the ADVANCE trial: first-line TAF/FTC/DTG, TDF/FTC/DTG vs TDF/FTC/EFV - weight gain - (08/01/22)   A propensity-score matched cohort study investigating premature age in people living with HIV - (08/01/22)   Switching From Integrase Inhibitor to PI Trims Weight in HIV Patient Database - Mark Mascolini - (08/01/22)   Update on neural tube defects with antiretroviral exposure in the Tsepamo Study, Botswana - (08/01/22)   Real-World Utilization of HIV Pre-Exposure Prophylaxis (PrEP) by Cisgender and Transgender Individuals in the United States - (08/01/22)   Week 48 of a phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/ tenofovir disoproxil fumarate (DTG+F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE) - Mark Mascolini - (07/30/22)   Long-Acting CAB Maintains Superiority to TDF/FTC in Preventing HIV in Women - Mark Mascolini - (07/30/22)   IBALIZUMAB LONG-TERM EFFICACY IS NOT IMPACTED BY PARTIALLY ACTIVE ANTIRETROVIRALS - (07/30/22)   Patrick Sullivan on AIDSVu's Landmark PrEP Use Data by Race/Ethnicity - (07/30/22)   Pharmacokinetic Modeling and Simulation of Intramuscular and Subcutaneous Ibalizumab Delivery - (07/30/22)   Doxycycline PEP Cuts Bacterial STI Rate Over 60% After Condomless Sex - Mark Mascolini - (07/30/22)   Trends in PrEP Inequity by Race and Census Region, USA, 2012-2021 - (07/30/22)   Long acting injectable cabotegravir: updated efficacy and safety results from HPTN 084 - (07/30/22)   Week 96 Weight and Lipid Changes From Baseline Among Participants Receiving Cabotegravir + Rilpivirine Long-Acting or Comparator Therapy in the ATLAS-2M and FLAIR Studies - (07/30/22)   Pharmacokinetics and Tolerability of Cabotegravir and Rilpivirine Long-Acting Intramuscular Injections to the Vastus Lateralis (Lateral Thigh) Muscles of Healthy Adult Participants - (07/29/22)   People With HIV Now Face Chronic Disease In Living Longer - (07/29/22)   Long-term Integrated Analysis of B/F/TAF in Treatment-Naïve Adults With HIV Through Five Years of Follow-up - (07/29/22)   Lipid Parameters and Lipid-Modifying Agent Use in Participants Initiating F/TAF or F/TDF for PrEP in the DISCOVER Trial - (07/29/22)   Real-World HIV Renal Outcomes With TDF to TAF Switch - (07/29/22)   Long-Acting Cabotegravir + Rilpivirine in Older Adults: Pooled Phase 3 Week 96 Results - (07/29/22)   Longitudinal Analysis of Weight Change in HIV-1 Treatment-Naïve and -Experienced People Living With HIV (PLWH) Initiating/Switching to an NNRTI- or INSTI-Based Antiretroviral Therapy in Four Large Cohort Studies - (07/29/22)   Injection-Site Reaction Experience in Clinical Studies of People Using Lenacapavir For HIV Treatment - (07/29/22)   Incidence of cardiometabolic outcomes among people living with HIV initiated on INSTI versus non-INSTI antiretroviral therapies - (07/29/22)   Can ART switch mitigate or reverse INSTI-related weight or BMI gain in high risk people living with HIV-1? - (07/29/22)   Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults With HIV-1: Week 240 Results of the Phase 3 BRIGHTE Study - (07/29/22)   ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced - (07/29/22)   AIDS 2022 News Release: Doxycycline Reduced STIs; Functional cure case; Stem Cell Transplant Cure Care; TAF vs TDF for HBV in ART regimen. - (07/29/22)   AVAC, BMGF, CIFF, MEDACCESS, UNITAID AND VIIV HEALTHCARE ANNOUNCE COLLABORATION TO CATALYSE MORE AFFORDABLE ACCESS TO LONG-ACTING CABOTEGRAVIR FOR HIV PREVENTION - (07/29/22)   ViiV HEALTHCARE AND THE MEDICINES PATENT POOL SIGN NEW VOLUNTARY LICENSING AGREEMENT TO EXPAND ACCESS TO INNOVATIVE LONG-ACTING HIV PREVENTION MEDICINE - (07/29/22)   AIDS 2022: New insights into HIV latent cells yield potential cure targets - (07/29/22)   AIDS 2022: Two HIV Patients Appear to Have Beaten Virus, Offering Hope for Cure - (07/29/22)   ViiV HEALTHCARE TO PRESENT NEW DATA FROM INNOVATIVE HIV TREATMENT AND PREVENTION PORTFOLIO AT AIDS 2022 - (07/22/22)   Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic - (07/22/22)